CTI BioPharma shares soar 83% after Swedish Orphan Biovitrum announces $1.7 billion deal for the biotech
Swedish Orphan Biovitrum AB, or Sobi, on Wednesday announced that it has entered into an agreement to acquire U.S.-based CTI BioPharma Corp. (CTIC) in a deal valued at $1.7 billion. Shares of CTI soared 83% in premarket trading, while Sobi stock fell 14% in Stockholm. The Swedish drugmaker said it will offer $9.10 for each share of CTI, which focuses on blood-related cancers and rare diseases. The offer represents a premium of 88.8% over CTI's the Tuesday closing price of $4.82 per share. "CTI represents a perfect fit for Sobi's haematology franchise today, adding a powerful and highly differentiated new product that will make a significant difference for patients", said Guido Oelkers, president and CEO of Sobi, in a statement. "There is a large unmet medical need within myelofibrosis, in particular for patients suffering from thrombocytopenia who are inadequately treated by existing medicines." Sobi said the acquisition is expected to be highly accretive to its revenue and margins, starting in the near-term. CTI's board of directors has unanimously approved the deal and recommended it to shareholders.
-Barbara Kollmeyer
This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.
(END) Dow Jones Newswires
05-10-23 0545ET
Copyright (c) 2023 Dow Jones & Company, Inc.-
How Anti-Obesity Drugs Are Innovating the Healthcare Market
-
What’s Happening In the Markets This Week
-
Why Immigration Has Boosted Job Gains and the Economy
-
What to Invest in During High Inflation
-
Never Mind Market Efficiency: Are the Markets Sensible?
-
Starbucks Stock Could Use a Pick-Me-Up After Big Selloff; Is it a Buy?
-
5 Cheap Stocks to Buy From an Attractive Part of the Market
-
Markets Brief: All Eyes On Inflation
-
After Earnings, Is Lyft Stock a Buy, a Sell, or Fairly Valued?
-
8 Stock Picks in the Apparel Industry
-
Baidu Earnings: Advertising Weakness Offset by Continued Growth In Cloud Business
-
Going Into Earnings, Is Target Stock a Buy, a Sell, or Fairly Valued?
-
Walmart Earnings: Low Prices and Strong Digital Presence Drive Market Share Gains
-
After Earnings and a Big Selloff, Is Shopify Stock a Buy, a Sell, or Fairly Valued?
-
Cisco Earnings: Positive Guidance and Splunk Inclusion Align With Our Long-Term Thesis
-
3 Warren Buffett Stocks to Buy After Berkshire Hathaway’s Just-Released 13F Filing